Abstract
Since 2012, several immune checkpoint inhibitors have been approved by the Taiwan FDA for various types of cancer treatment. However, none of them are covered by Taiwan National Health Insurance due to the fact that they are expensive, and there is a lack of clinical evidence as to their effectiveness. This study was aimed toward an exploration of clinical experiences with use of immune checkpoint inhibitors, including indications, prescription types, drug effectiveness, adverse drug event types, and incidence, all of which shall serve as references for future clinical drug use. This is a retrospective study focusing on three immune checkpoint inhibitors (ipilimumab, nivolumab, and pembrolizumab), which are available for cancer treatment in Taiwan. We collected data from medical records for the period from January 1st, 2015 to January 12th, 2017 at National Cheng Kung University Hospital (NCKUH), a medical center in southern Taiwan, and recorded these cases until May 31st, 2017. Overall survival (OS) and progression-free survival (PFS) were estimated using the Kaplan-Meier method, and adverse drug reaction odds ratios were analyzed using a chi-square analysis. The 50 patients under consideration in this study had used any one o...Continue Reading
References
Nov 18, 2014·The New England Journal of Medicine·Caroline RobertPaolo A Ascierto
Dec 3, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Robert J MotzerHans J Hammers
Apr 5, 2015·The Lancet Oncology·Alexander M M EggermontAlessandro Testori
Apr 22, 2015·The New England Journal of Medicine·Caroline RobertUNKNOWN KEYNOTE-006 investigators
Apr 22, 2015·The New England Journal of Medicine·Michael A PostowF Stephen Hodi
Apr 22, 2015·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Scott N GettingerJulie R Brahmer
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Jun 28, 2015·The Lancet Oncology·Antoni RibasAdil Daud
Sep 24, 2015·The New England Journal of Medicine·James LarkinJedd D Wolchok
Sep 24, 2015·The New England Journal of Medicine·Matias E Valsecchi
Sep 26, 2015·The New England Journal of Medicine·Robert J MotzerUNKNOWN CheckMate 025 Investigators
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Dec 30, 2015·Lancet·Roy S HerbstEdward B Garon
Feb 11, 2016·Immunotherapy·Bing Xia, Roy S Herbst
Jun 9, 2016·The Lancet Oncology·Scott J AntoniaEmiliano Calvo
Oct 9, 2016·The New England Journal of Medicine·Alexander M M EggermontAlessandro Testori
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Oct 18, 2016·The Lancet Oncology·Corey J LangerUNKNOWN KEYNOTE-021 investigators
Jan 6, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Sandra P D'AngeloJedd D Wolchok
Feb 9, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·R HuiN A Rizvi
Jun 22, 2017·The New England Journal of Medicine·David P CarboneUNKNOWN CheckMate 026 Investigators
Oct 19, 2017·Chemotherapy·Pablo Calpe-ArmeroAlejandro Pérez-Pitarch
Feb 7, 2018·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E E VokesL Crinò
Feb 8, 2018·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Clément GauvainIsabelle Monnet
Apr 17, 2018·The New England Journal of Medicine·Leena GandhiUNKNOWN KEYNOTE-189 Investigators
Citations
Jul 18, 2019·Frontiers in Pharmacology·Jiqiao YangHubing Shi
May 6, 2019·JAMA Network Open·Alyson Haslam, Vinay Prasad
Sep 29, 2020·Future Science OA·Edward B MaldonadoVinay Prasad
Mar 11, 2021·Science Progress·Mohammed Al NuhaitYousef Al Awlah
Jul 27, 2021·Frontiers in Oncology·Jason C HsuChristine Y Lu
Jul 2, 2019·Asia-Pacific Journal of Oncology Nursing·Fedricker Diane Barber